A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors.
Open accessThe DOI matches its Crossref record; 41 of the 43 references it cites were found in a registry or an index; 7 of the 30 sources its claims cite were checked for support.
Abstract
We found significant linkage to a locus that includes the XPNPEP2 candidate gene encoding membrane-bound APP. Mutation screening of this QTL identified a large coding deletion segregating in one pedigree and an upstream single-nucleotide polymorphism (C-2399A SNP) which regulates APP activity. We found significant association of this SNP to ACEi-induced AE.
Overview
CoChat Summary
TL;DR
A genomewide linkage and candidate-gene study found that plasma aminopeptidase P (APP) activity is partly heritable and links to the XPNPEP2 locus, where a C-2399A variant is associated with reduced APP activity and ACE inhibitor–induced angioedema. The authors conclude that this variant may contribute to susceptibility to a potentially fatal adverse drug reaction.
Key findings
- Plasma APP activity was heritable: 37.5% ± 26.5% in cohort 1 (P = .0336) and 33.6% ± 25.1% in all eight pedigrees combined (P = .0452).
- Variance-component linkage analysis found a maximum two-point LOD score of 3.75 at the XPNPEP2_CA marker near XPNPEP2 in combined cohorts 1 and 2.
- Mutation screening identified a 175-bp coding deletion (g.2953-3127del) in XPNPEP2 in one pedigree, predicted to produce a truncated 38-amino-acid protein, and an upstream C-2399A SNP segregating in seven of eight pedigrees.
- The C-2399A SNP significantly accounted for the linkage signal: excluding the deletion pedigree, the XPNPEP2_CA linkage LOD dropped from 3.24 to 0.54, and the SNP was a significant covariate (P < .0001; proportion of variance explained = 0.3149).
- In a case-control sample of 20 AE-ACEi cases and 60 controls, the A allele frequency was 27.3% in cases versus 11.1% in controls, with association P = .0364 by Armitage trend test.
Methods
- Eight white pedigrees (cohort 1: five pedigrees, 88 DNA samples; cohort 2: three pedigrees, 35 DNA samples; 123 participants total) were selected because one member per family had a history of ACEi-associated angioedema and/or anaphylactoid reaction. Plasma APP activity was measured as the quantitative trait.
- A 10-cM genomewide microsatellite scan (397 markers) enriched with seven markers around APP candidate regions was performed in cohort 1, followed by variance-component QTL linkage analysis in SOLAR; cohort 2 was genotyped for 11 markers covering regions with LOD > 1 and the XPNPEPL locus.
- Mutation detection used SSCP, sequencing, RFLP, and allele-specific PCR for XPNPEP2 and XPNPEPL; mRNA from lymphoblastoid cells was analyzed for the deletion’s splicing effect. The case-control association used 20 AE-ACEi cases and 60 controls matched by country of origin and gender.
Limitations
- The paper states that clinical diagnosis was not used in linkage analysis because of lack of power; controls were not matched for age; medical histories were unknown for US controls; and the biological significance of the C-2399A SNP remains undetermined.
- The paper also states that functional expression analysis was unsuccessful because XPNPEP2 is poorly expressed in human lymphoblastoid cells, and that further investigation of other linked loci is necessary.
- Evident from the text: the case-control association is small (20 cases, 60 controls) and not replicated; controls from Belgium and Canada had no history of ACEi therapy, so not all controls were ACEi-exposed; and only 9 of 20 AE-ACEi cases carried the identified variants, with one-third of cases having normal or high APP activity, indicating that the variant explains only a fraction of AE-ACEi risk.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
5 Valid · 1 Not valid · 15 Not checked · 34 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“These mean values for AEACEi patients differ from those previously reported in healthy whites (24 H11506 9 units and 19 H11506 7 units in women and men, respectively) (Cyr et al. 2001).”
What the sources say
- Supportedcites Cyr et al. 2001 source
The Methods (p. 3) identify the reference group as 116 healthy Caucasian volunteers. The Results (p. 5) report mean serum APP activity of 24 ± 9 in women and 19 ± 7 in men. The comparison with AE-ACEi patients is the citing authors’ own comparison, not a result attributed to this source. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Measured genotype analysis strongly suggests that the linkage signal for APP activity at this locus is accounted for predominantly by the SNP association.”
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We found significant linkage (LOD p 3.75) to a locus that includes the XPNPEP2 candidate gene encoding membrane-bound APP.”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“With eight large pedigrees, we hereby demonstrate that this quantitative trait is partially regulated by genetic factors.”
boostedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, we show a significant association between the C-2399A polymorphism and AE-ACEi.”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
22 more claims
Create a free account to see all 55 claims and every source verdict.
- It may state two separate claims as one. 19
- Probably not a substantial claim. 19
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is similar to the estimated heritability of plasma APP of 37.5 ± 26.5% from a smaller study of eight pedigrees selected on the basis of one family member with ACEi-angioedema and/or other anaphylactoid responses to ACEi”
From A functional XPNPEP2 promoter haplotype leads to reduced plasma aminopeptidase P and increased risk of ACE inhibitor‐induced angioedema (2011) · cites this paper as Duan et al., 2005
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The frequency of the −2399A allele was also increased in 20 mixed-gender cases of ACE inhibitor-associated angioedema as compared to 60 ACE inhibitor-exposed controls.[11]”
From Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema (2010) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This variant segregated with reduced serum APP activity in families in which the proband had ACE inhibitor-associated angioedema or anaphylactoid reaction during dialysis.[11]”
From Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema (2010) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“this study also identified a QTL with peak LOD = 3.75 in the vicinity of the gene encoding APP (XPNPEP2) [Duan et al., 2005].”
From A functional XPNPEP2 promoter haplotype leads to reduced plasma aminopeptidase P and increased risk of ACE inhibitor‐induced angioedema (2011) · cites this paper as Duan et al., 2005
The cited source says what the claim attributes to it.
In the citing paper
“A single nucleotide polymorphism, −2399C>A (rs3788853, C-2399A), in XPNPEP2, the X-linked gene that encodes membranous APP, has been reported to associate with APP activity.”
From Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema (2010) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Introduction · p. 2
“The gene encoding the former is XPNPEP2 (MIM 300145), localized to chromosome Xq26.1 (Sprinkle et al. 1998)”
§ References · p. 10
“Assignment of the membrane-bound human aminopeptidase P gene (XPNPEP2) to chromosome Xq25.”
Citations
Cites
An Analysis of Transformations
Box, G. E. P., & Cox, D. R. (1964) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1964.tb00553.x · Cited by 15,052
Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites
Nielsen, H., Engelbrecht, J., Brunak, S., & von Heijne, G. (1997) · Protein Engineering Design and Selection · doi:10.1093/protein/10.1.1 · Cited by 5,356
Multipoint Quantitative-Trait Linkage Analysis in General Pedigrees
Almasy, L., & Blangero, J. (1998) · The American Journal of Human Genetics · doi:10.1086/301844 · Cited by 3,028
Bioregulation of kinins: kallikreins, kininogens, and kininases.
Bhoola, K. D., Figueroa, C. D., & Worthy, K. (1992) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00058-4 · Cited by 1,744
Angiotensin-Converting Enzyme Inhibitors
Brown, N. J., & Vaughan, D. E. (1998) · Circulation · doi:10.1161/01.cir.97.14.1411 · Cited by 958 · cited 1×
“Angiotensin I–converting enzyme inhibitors (ACEi) are a class of drugs used by 140 million patients worldwide for the treatment of cardiovascular diseases such as hypertension, congestive heart failure, and diabetes (Unger and Gohlke 1994; Brown and Vaughan 1998).”
BackgroundSelf-citationIsraili, Z. H., & Hall, W. D. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-3-234 · Cited by 910 · cited 2×
“7% of white patients (Israili and Hall 1992; Vleeming et al. 1998) and is four to five times more prevalent among”
BackgroundPlasma bradykinin in angio-oedema
Nussberger, J., Cugno, M., Amstutz, C., Cicardi, M., Pellacani, A., & Agostoni, A. (1998) · The Lancet · doi:10.1016/s0140-6736(97)09137-x · Cited by 706
Self-citationAgostoni, A., Aygören-Pürsün, E., Binkley, K. E., Blanch, A., Bork, K., Bouillet, L., Bucher, C., Castaldo, A. J., Cicardi, M., Davis, A. E., et al. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.06.047 · Cited by 646
Self-citationTrans-acting regulatory variation in Saccharomyces cerevisiae and the role of transcription factors
Yvert, G., Brem, R. B., Whittle, J., Akey, J. M., Foss, E., Smith, E. N., Mackelprang, R., & Kruglyak, L. (2003) · Nature Genetics · doi:10.1038/ng1222 · Cited by 632
Kostis, J. (2004) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2003.09.014 · Cited by 579
Brown, N. J., Ray, W. A., Snowden, M., & Griffin, M. R. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90161-7 · Cited by 313 · cited 1×
“00 African Americans (Brown et al. 1996; Coats 2002).”
BackgroundSelf-citationEstrogen regulation of angiotensin-converting enzyme mRNA
Gallagher, P. E., Li, P., Lenhart, J. R., Chappell, M. C., & Brosnihan, K. B. (1999) · Hypertension · doi:10.1161/01.hyp.33.1.323 · Cited by 290 · cited 1×
“, smoking and hormone replacement therapy [Gallagher et al. 1999]).”
BackgroundACE Inhibitor???Induced Angioedema: Incidence, Prevention and Management
Vleeming, W., van Amsterdam, J. G. C., Stricker, B. H., & de Wildt, D. J. (1998) · Drug Safety · doi:10.2165/00002018-199818030-00003 · Cited by 243 · cited 1×
“7% of white patients (Israili and Hall 1992; Vleeming et al. 1998) and is four to five times more prevalent among”
BackgroundBradykinin and the pathophysiology of angioedema
Cugno, M., Nussberger, J., Cicardi, M., & Agostoni, A. (2003) · International Immunopharmacology · doi:10.1016/s1567-5769(02)00162-5 · Cited by 215 · cited 1×
“An increase of BK has been measured in the plasma of patients during episodes of AE-ACEi, but, unlike hereditary forms of AE (MIM 106100), there is no increase in cleavage of the BK precursor, high-molecularweight kininogen (HK) (Nussberger et al. 1998; Agostoni et al. 1999; Cugno et al. 2003).”
BackgroundSelf-citationSingle-tube genotyping without oligonucleotide probes
Germer, S., & Higuchi, R. (1999) · Genome Research · doi:10.1101/gr.9.1.72 · Cited by 199 · cited 1×
“The C-2399A SNP was genotyped using a modification of the allele-specific PCR assay described elsewhere (Germer and Higuchi 1999).”
MethodAminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors
Adam, A., Cugno, M., Molinaro, G., Perez, M., Lepage, Y., & Agostoni, A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08914-6 · Cited by 181
Self-citationBradykinin and des-Arg9-bradykinin metabolic pathways and kinetics of activation of human plasma
Cyr, M., Lepage, Y., Blais, C., Gervais, N., Cugno, M., Rouleau, J.-L., & Adam, A. (2001) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2001.281.1.h275 · Cited by 160 · cited 5×
“This carboxytruncated metabolite is, in turn, broken down by APP and ACE (Cyr et al. 2001).”
BackgroundResultInfluentialSelf-citationDrug-Induced Angioedema without Urticaria: Incidence, Prevention and Management
Agostoni, A., & Cicardi, M. (2001) · Drug Safety · doi:10.2165/00002018-200124080-00004 · Cited by 154
Self-citationAngioedema due to angiotensin-converting enzyme inhibitors
Agostoni, A., Cicardi, M., Cugno, M., Zingale, L. C., Gioffré, D., & Nussberger, J. (1999) · Immunopharmacology · doi:10.1016/s0162-3109(99)00107-1 · Cited by 147 · cited 1×
“An increase of BK has been measured in the plasma of patients during episodes of AE-ACEi, but, unlike hereditary forms of AE (MIM 106100), there is no increase in cleavage of the BK precursor, high-molecularweight kininogen (HK) (Nussberger et al. 1998; Agostoni et al. 1999; Cugno et al. 2003).”
BackgroundSelf-citationMolinaro, G., Cugno, M., Perez, M., Lepage, Y., Gervais, N., Agostoni, A., & Adam, A. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.038067 · Cited by 137
Self-citationThe kallikrein-kininogen-kinin system: lessons from the quantification of endogenous kinins
Blais, C., Marceau, F., Rouleau, J.-L., & Adam, A. (2000) · Peptides · doi:10.1016/s0196-9781(00)00348-x · Cited by 135
Self-citationSoria, J. M., Almasy, L. A., Souto, J. C., Tirado, I., Borrell, M., Mateo, J., Slifer, S., Stone, W. H., Blangero, J., & Fontcuberta, J. (2000) · Blood · doi:10.1182/blood.v95.9.2780.009k36_2780_2785 · Cited by 120
Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema
Lefebvre, J., Murphey, L. J., Hartert, T. V., Jiao Shan, R., Simmons, W. H., & Brown, N. J. (2002) · Hypertension · doi:10.1161/hy0202.103054 · Cited by 113 · cited 2×
“Other potential risk factors include elevated levels of the sensory neuropeptide substance P, which correlate with reduced amounts of dipeptidyl peptidase IV activity (Ferreira et al. 2000; Lefebvre et al. 2002).”
BackgroundResultSelf-citationOmapatrilat—the story of Overture and Octave
Coats, A. J. S. (2002) · International Journal of Cardiology · doi:10.1016/s0167-5273(02)00389-3 · Cited by 107 · cited 2×
“00 African Americans (Brown et al. 1996; Coats 2002).”
BackgroundSimmons, W. H., & Orawski, A. T. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42915-8 · Cited by 97
Blais, C., Rouleau, J.-L., Brown, N. J., Lepage, Y., Spence, D., Munoz, C., Friborg, J., Geadah, D., Gervais, N., & Adam, A. (1999) · Immunopharmacology · doi:10.1016/s0162-3109(99)00133-2 · Cited by 78
Self-citationExploring Positional Candidate Genes: Linkage Conditional on Measured Genotype
Almasy, L. A., & Blangero, J. (2004) · Behavior Genetics · doi:10.1023/b:bege.0000013731.03827.69 · Cited by 63
Inhibition by converting enzyme inhibitors of pig kidney aminopeptidase P.
Hooper, N. M., Hryszko, J., Oppong, S. Y., & Turner, A. J. (1992) · Hypertension · doi:10.1161/01.hyp.19.3.281 · Cited by 62
Converting enzyme inhibitors in cardiovascular therapy: current status and future potential
Unger, T., & Gohlke, P. (1994) · Cardiovascular Research · doi:10.1093/cvr/28.2.146 · Cited by 60 · cited 1×
“Angiotensin I–converting enzyme inhibitors (ACEi) are a class of drugs used by 140 million patients worldwide for the treatment of cardiovascular diseases such as hypertension, congestive heart failure, and diabetes (Unger and Gohlke 1994; Brown and Vaughan 1998).”
BackgroundBlais, C., Marc–Aurèle, J., Simmons, W. H., Loute, G., Thibault, P., Skidgel, R. A., & Adam, A. (1999) · Peptides · doi:10.1016/s0196-9781(99)00020-0 · Cited by 60
Self-citationAminopeptidases in Biology and Disease
(2004) · Springer eBooks · doi:10.1007/978-1-4419-8869-0 · Cited by 48
Kim, K.-S., Kumar, S., Simmons, W. H., & Brown, N. J. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35290-5 · Cited by 45
Self-citationCloning and tissue distribution of human membrane-bound aminopeptidase P
Venema, R. C., Ju, H., Zou, R., Venema, V. J., & Ryan, J. W. (1997) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(97)00126-7 · Cited by 37
Assignment of the Membrane-Bound Human Aminopeptidase P Gene (XPNPEP2) to Chromosome Xq25
Sprinkle, T. J., Stone, A. A., Venema, R. C., Denslow, N. D., Caldwell, C., & Ryan, J. W. (1998) · Genomics · doi:10.1006/geno.1998.5302 · Cited by 34
Sprinkle, T. J., Caldwell, C., & Ryan, J. W. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2000.1792 · Cited by 25 · cited 1×
“1 (Sprinkle et al. 2000).”
Ferreira, P. K., Campos, M. M., & Calixto, J. Β. (2000) · Regulatory Peptides · doi:10.1016/s0167-0115(00)00094-x · Cited by 25
Aminopeptidase P and Vasoactive Peptides
Molinaro, G., Boileau, G., & Adam, A. A. (2004) · Springer eBooks · doi:10.1007/978-1-4419-8869-0_12 · Cited by 8
Self-citationPreliminary survey of the occurrence of anaphylactoid reactions during haemodialysis
Bright, R., Torrence, M. E., Daley, W., & McClellan, W. (1999) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/14.3.799 · Cited by 7
Blais (1997) · doi:10.1002/1529-0131(199707)40:7<1327::aid-art18>3.0.co;2-b
Self-citationBlais, C., Couture, R., Drapeau, G., et al. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400718
Cited by
Cicardi, M., Aberer, W., Banerji, A., Bas, M., Bernstein, J. A., Bork, K., Caballero, T., Farkas, H., Grumach, A., Kaplan, A. P., et al. (2014) · Allergy · doi:10.1111/all.12380 · Cited by 666
Mangiafico, S., Costello-Boerrigter, L. C., Andersen, I. A., Cataliotti, A., & Burnett, J. C. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs262 · Cited by 276
“Similarly, individuals with XPNPEP2 genetic variations that result in lower APP levels are also more apt to have ACE-inhibitor-associated angioedema.(98,99) In this age of pharmacogenomics and personalized therapy, the incidence of angioedema may be decreased by not giving genetically predisposed subjects such a medic…”
BackgroundAngioedema without urticaria: a large clinical survey
Zingale, L. C., Beltrami, L., Zanichelli, A., Maggioni, L., Pappalardo, E., Cicardi, B., & Cicardi, M. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.060535 · Cited by 218
Factors predicting anaphylaxis to peanuts and tree nuts in patients referred to a specialist center
Summers, C. W., Pumphrey, R. S., Woods, C. N., McDowell, G., Pemberton, P. W., & Arkwright, P. D. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.12.003 · Cited by 185
New topics in bradykinin research
Maurer, M., Bader, M., Bas, M., Bossi, F., Cicardi, M., Cugno, M., Howarth, P., Kaplan, A., Kojda, G., Leeb‐Lundberg, F., et al. (2011) · Allergy · doi:10.1111/j.1398-9995.2011.02686.x · Cited by 176
“Why angioedema tends to recur in these patients is unclear but may be due to an abnormality in bradykinin degradation – as demonstrated for an APP variant (61) – which becomes clinically relevant when ACE is pharmacologically blocked.”
BackgroundSelf-citation
Metadata
- Authors
- Duan, Q. L., Nikpoor, B., Dubé, M.-P., Molinaro, G., Meijer, I. A., Dion, P., Rochefort, D., Saint-Onge, J., Flury, L., Brown, N. J., Gainer, J. V., Rouleau, J. L., Agostoni, A., Cugno, M., Simon, P., Clavel, P., Potier, J., Wehbe, B., Benarbia, S., Marc-Aurèle, J., Chanard, J., Foroud, T., Adam, A., & Rouleau, G. A.
- Affiliations
- Hôpital Notre-Dame (CA)
- Montreal Heart Institute (CA)
- Université de Montréal (CA)
- Vanderbilt University (US)
- University of Milan (IT)
- Centre Hospitalier de Saint-Brieuc (FR)
- Centre Hospitalier Universitaire de Reims (FR)
- Centre Hospitalier de Cornouaille (FR)
- Hôpital de Saint-Jérôme (CA)
- Indiana University Indianapolis (US)
- Corresponding author
- Rouleau, Guy A.
- ORCID
- Venue
- The American Journal of Human Genetics
- Publisher
- Elsevier BV
- Published
- 2005-10
- Volume
- 77
- Issue
- 4
- Pages
- 617-626
- ISSN
- 0002-9297 (ISSN-L)
- PMC
- PMC1275610
- OpenAlex
- W2141319262
- Cited by
- 126
- References
- 43
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 4 · 2023: 3 · 2021: 6 · 2020: 4 · 2019: 5 · 2018: 5 · 2017: 6 · 2016: 8 · 2015: 8 · 2014: 8 · 2013: 8 · 2012: 11
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 2848 d)
- Locations
- The American Journal of Human Genetics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Funders
- McGill University
- National Institutes of Health
- Canadian Institutes of Health Research
- National Heart, Lung, and Blood Institute (R01HL079184)
- Topics
- Health Sciences › Medicine › Hematology › Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- angioedema, ACE inhibitors, aminopeptidase P, genetic susceptibility, single nucleotide polymorphisms, linkage analysis, quantitative trait loci, plasma enzyme activity, adverse drug reactions
- MeSH terms
- Aminopeptidases, Angioedema, Angiotensin-Converting Enzyme Inhibitors, Female, Humans, Genetic Linkage, Male, Mutation, Pedigree, Cohort Studies, Quantitative Trait Loci
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.